MX2023003785A - Inhibidores de imidazopiperazina de proteinas de activacion de transcripcion. - Google Patents

Inhibidores de imidazopiperazina de proteinas de activacion de transcripcion.

Info

Publication number
MX2023003785A
MX2023003785A MX2023003785A MX2023003785A MX2023003785A MX 2023003785 A MX2023003785 A MX 2023003785A MX 2023003785 A MX2023003785 A MX 2023003785A MX 2023003785 A MX2023003785 A MX 2023003785A MX 2023003785 A MX2023003785 A MX 2023003785A
Authority
MX
Mexico
Prior art keywords
inhibitors
imidazopiperazine
diseases
activating proteins
transcription activating
Prior art date
Application number
MX2023003785A
Other languages
English (en)
Spanish (es)
Inventor
Michael Soth
Kang Le
Philip Jones
Jason Cross
Timothy Mcafoos
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2023003785A publication Critical patent/MX2023003785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023003785A 2020-10-02 2021-09-30 Inhibidores de imidazopiperazina de proteinas de activacion de transcripcion. MX2023003785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086728P 2020-10-02 2020-10-02
PCT/US2021/052898 WO2022072648A1 (en) 2020-10-02 2021-09-30 Imidazopiperazine inhibitors of transcription activating proteins

Publications (1)

Publication Number Publication Date
MX2023003785A true MX2023003785A (es) 2023-04-26

Family

ID=80950902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003785A MX2023003785A (es) 2020-10-02 2021-09-30 Inhibidores de imidazopiperazina de proteinas de activacion de transcripcion.

Country Status (14)

Country Link
US (2) US12559497B2 (cg-RX-API-DMAC7.html)
EP (1) EP4221709B1 (cg-RX-API-DMAC7.html)
JP (1) JP7865951B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230080441A (cg-RX-API-DMAC7.html)
CN (1) CN116261454A (cg-RX-API-DMAC7.html)
AU (1) AU2021355480B2 (cg-RX-API-DMAC7.html)
CA (1) CA3193745A1 (cg-RX-API-DMAC7.html)
DK (1) DK4221709T3 (cg-RX-API-DMAC7.html)
ES (1) ES3068299T3 (cg-RX-API-DMAC7.html)
IL (1) IL301707A (cg-RX-API-DMAC7.html)
MX (1) MX2023003785A (cg-RX-API-DMAC7.html)
PL (1) PL4221709T3 (cg-RX-API-DMAC7.html)
PT (1) PT4221709T (cg-RX-API-DMAC7.html)
WO (1) WO2022072648A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
AU2024331409A1 (en) * 2023-08-30 2026-03-12 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as cbp/p300 degraders and uses thereof
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270143T3 (es) 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2007139992A2 (en) 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2013050446A1 (en) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
CN103087067A (zh) 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物,以及它们的用途
WO2014062548A1 (en) 2012-10-18 2014-04-24 Bristol-Myers Squibb Company Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN107108512B (zh) 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3632915A1 (en) * 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제

Also Published As

Publication number Publication date
DK4221709T3 (da) 2026-04-07
IL301707A (en) 2023-05-01
EP4221709A4 (en) 2024-10-02
ES3068299T3 (en) 2026-05-28
CA3193745A1 (en) 2022-04-07
AU2021355480B2 (en) 2026-03-05
US20230312588A1 (en) 2023-10-05
EP4221709A1 (en) 2023-08-09
US12559497B2 (en) 2026-02-24
PL4221709T3 (pl) 2026-08-10
JP7865951B2 (ja) 2026-05-26
EP4221709B1 (en) 2026-01-21
CN116261454A (zh) 2023-06-13
KR20230080441A (ko) 2023-06-07
AU2021355480A1 (en) 2023-05-04
US20260132138A1 (en) 2026-05-14
JP2023544173A (ja) 2023-10-20
AU2021355480A9 (en) 2024-09-12
WO2022072648A1 (en) 2022-04-07
PT4221709T (pt) 2026-04-24

Similar Documents

Publication Publication Date Title
ZA202310316B (en) Fluoroalkyl-oxadiazoles and uses thereof
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
JOP20230170A1 (ar) مثبطات cdk2 وطرق لاستخدامها
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
EA202192746A1 (ru) Гетероциклические соединения и их применение
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2022000845A (es) Compuestos inhibidores.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
WO2020021480A3 (en) Compositions and methods for treating the eye
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY